ImmusanT, Inc.'s Epitope-Specific Immunotherapy for Celiac Disease Informs the Potential of Vaccines Against Other Autoimmune Diseases
4/22/2013 9:47:47 AM
More...
|
New Insight Into Celiac Disease, Monash University, University of Leiden, and ImmusanT, Inc. Study
10/12/2012 7:32:19 AM
More...
|
ImmusanT, Inc. Initiates Clinical Trials of Nexvax2 Therapeutic Vaccine for Celiac Disease
9/4/2012 10:57:45 AM
More...
|
ImmusanT, Inc. Relocates Offices to State-of-the-Art Innovation Facility
8/16/2012 10:42:44 AM
More...
|
Sanofi (France) (SAN.PA)'s Patrick Griffin Joins Celiac Start-up ImmusanT, Inc.
3/19/2012 9:56:24 AM
More...
|
ImmusanT, Inc. Raises $20 Million in Series A Financing to Advance Immunotherapeutic and Diagnostic for Celiac Disease
12/13/2011 6:40:47 AM
More...
|
ImmusanT, Inc. Reports Positive Results from Nexvax2 Phase 1 Study in Celiac Disease
5/9/2011 7:53:18 AM
More...
|
Start-Up ImmusanT, Inc. Seeks to Restore Tolerance to Gluten in Celiac Disease with Immunotherapy
3/15/2011 6:47:02 AM
More...
|